Developments FDA provides positive feedback on Appili’s ATI-1801 for CL Appili Therapeutics (TSX:APLI; OTCPink:APLIF) announced that the FDA has provided positive feedback on the development strategy and NDA application for the company’s ATI-1801 for cutaneous leishmaniasis (CL). ATI-1801... October 31, 2024